| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| July 24, 2026 | ±3.5% | +0.4% | over-priced |
| April 24, 2026 | ±2.8% | -0.1% | over-priced |
| October 24, 2025 | ±2.1% | +0.2% | over-priced |
| July 25, 2025 | ±1.8% | +0.9% | over-priced |
| April 30, 2025 | ±2.6% | +1.7% | over-priced |
| November 8, 2024 | ±2.1% | +1.6% | over-priced |
| August 5, 2024 | ±2.1% | -1.3% | over-priced |
| May 1, 2024 | ±2.1% | -0.8% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $2.88 | $1.7B | $1.0B |
| Q1 FY2026 | $3.18 | $1.9B | $1.2B |
| Q4 FY2025 | $3.24 | $1.6B | $1.2B |
| Q3 FY2025 | $2.49 | $1.5B | $908M |
CME Group Inc. (CME) reports in 108 days, with the next report estimated for November 13, 2026. Across the last 8 reports, options priced an average ±2.4% earnings move while the stock actually moved 0.9% on average — the market has systematically over-priced CME's earnings risk. Fundamentals into the print: EPS up 2.5% year-over-year, revenue up 0.8%. QuantLogix's live 5-factor engine currently reads CME as a sell at 41/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →